Core Viewpoint - The company, Betta Pharmaceuticals (300558.SZ), has received acceptance from the National Medical Products Administration (NMPA) for its application for the marketing authorization of Ensartinib capsules (brand name: Beimei Na) for postoperative adjuvant therapy in patients with ALK-positive stage IB to IIIB non-small cell lung cancer (NSCLC) who have previously undergone surgical resection and have a physician's decision on adjuvant chemotherapy [1] Group 1 - The NMPA issued an acceptance notice for the company's application [1] - The application is for Ensartinib capsules intended for specific NSCLC patients [1] - The targeted patient population includes those who have undergone surgical treatment and are ALK-positive [1]

Core Viewpoint - The announcement indicates that the company has received acceptance from the National Medical Products Administration (NMPA) for its application of a new drug, which is a significant step towards potential market entry for the treatment of specific lung cancer patients [1] Group 1: Company Information - The company, Betta Pharmaceuticals (stock code: 300558), has announced that it received an acceptance notice from the NMPA for its application of the drug, Enasidenib Hydrochloride Capsules (brand name: Baimena®) [1] - The drug is intended for postoperative adjuvant therapy in patients with ALK-positive non-small cell lung cancer (NSCLC) at stages IB to IIIB, who have previously undergone surgical resection [1] - The decision for patients to receive or not receive adjuvant chemotherapy will be made by their physicians [1] Group 2: Industry Context - The acceptance of the drug application by NMPA represents a crucial regulatory milestone in the pharmaceutical industry, particularly for oncology treatments [1] - The focus on ALK-positive NSCLC highlights the ongoing advancements and targeted therapies being developed within the cancer treatment sector [1]

证券代码：300558 证券简称：贝达药业 公告编号：2025-072 贝达药业股份有限公司 关于盐酸恩沙替尼胶囊术后辅助治疗适应症药品注册申请获得受理的 公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 贝达药业股份有限公司（以下简称"贝达药业"或"公司"）收到国家 药品监督管理局（以下简称"NMPA"）签发的《受理通知书》（受理号： CXHS2500142、CXHS2500143），公司申报的盐酸恩沙替尼胶囊（商品名：贝美 纳®，以下简称"恩沙替尼"）拟用于"间变性淋巴瘤激酶（ALK）阳性的 IB 期 至 IIIB 期非小细胞肺癌（NSCLC）患者的术后辅助治疗，患者须既往接受过手术 切除治疗，并由医生决定接受或不接受辅助化疗"的上市许可申请已获得 NMPA 受理，现将具体情况公告如下： 一、申请注册药品的基本情况 产品名称：盐酸恩沙替尼胶囊 恩沙替尼"适用于 ALK 阳性的局部晚期或转移性的 NSCLC 患者的治疗"（新增 一线适应症）于 2022 年 3 月获得 NMPA 批准。2023 年 12 月，恩沙替尼纳入《国 家基本医疗保险、工伤保险和生 ...

Core Viewpoint - Boda Pharmaceutical's stock has experienced a decline of 5.98% year-to-date, with significant drops over various time frames, indicating potential challenges in the market [1][2]. Financial Performance - For the period from January to September 2025, Boda Pharmaceutical achieved a revenue of 2.717 billion yuan, reflecting a year-on-year growth of 15.90%. However, the net profit attributable to shareholders decreased by 23.86% to 317 million yuan [2]. - Cumulative cash dividends since the company's A-share listing amount to 669 million yuan, with 184 million yuan distributed over the past three years [3]. Stock Market Activity - As of November 26, Boda Pharmaceutical's stock price was 50.52 yuan per share, with a market capitalization of 21.255 billion yuan. The stock saw a net inflow of 4.3816 million yuan from main funds [1]. - The company has seen a decrease in shareholder accounts, with a total of 29,500 shareholders as of September 30, down by 7.99%. The average number of circulating shares per person increased by 8.68% to 14,198 shares [2]. Shareholder Composition - As of September 30, 2025, the top ten circulating shareholders include new entrants such as Xingquan Commercial Model Mixed Fund A and Xingquan Helun Mixed Fund A, while some funds like China Europe Medical Health Mixed Fund A have exited the top ten list [3].

来源：市场资讯 （来源：深蓝观） 李昀 | 撰文 王晨 | 编辑 今年，港股融资形式大好，不少公司想抓住这一波机会，因此IPO也出现了严重堵车的情况。 据中证报，今年以来，港股市场已有87只新股IPO上市，IPO募资总额超2400亿港元，位居全球交易所首位。今年以来共有16家 A股上市公司成功登陆港股市场，超80家A股上市公司已在港交所排队。 港交所行政总裁陈翊庭在接受媒体采访时也透露，目前正在处理的上市申请大概有300家。 今年在香港上市的生物医药企业也格外多。恒瑞、映恩等23家企业登录港股，仅上个月最后一周就有8家企业相继提交上市申 请。 "并不单单是要赶港股行情上升的窗口期，"一名投资人这样解释创新药的IPO热，"同时还要抓住这一波出海的机会。其实还是 挺生死攸关的。没有融资，就做不了BD需要的数据，很可能就错过这十几年难遇的红利。" 一位长期关注一级市场的投资人向我们表示，当前企业在选择上市地点时，港股依然是优先项：节奏更快、确定性更高、募资 更灵活、市场反馈更直接。尤其在创新药领域，大多数企业仍处于未盈利阶段，而科创板尽管近来有"开闸"迹象，但多数创新 药企业仍难以满足其盈利或细分指标要求。在这样的 ...

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology sector [5]. Core Insights - The report emphasizes the importance of seizing opportunities following market corrections, particularly in anticipation of improvements in 2026. It notes that the pharmaceutical sector's fundamentals remain strong despite recent market fluctuations, and it is currently at a valuation bottom. The report suggests focusing on innovative drugs and companies with potential for operational improvements in 2025 [7][11]. Summary by Sections Industry Overview - The pharmaceutical sector consists of 498 listed companies with a total market capitalization of approximately 70,594.11 billion [2]. - The sector has experienced a decline of 6.88% recently, with various sub-sectors such as pharmaceutical commerce and biopharmaceuticals also facing downturns [11]. Market Dynamics - The report highlights a significant market correction, with the Shanghai Composite Index down by 3.77% and the pharmaceutical sector underperforming [11]. - It notes that the overall performance of the pharmaceutical sector has been positive since the beginning of the year, with a return of 13.69%, slightly outperforming the broader market [18]. Investment Opportunities - The report identifies key companies to watch, including: - CDMO leaders: WuXi AppTec, WuXi Biologics, and WuXi AppTec [11]. - Front-end CROs: Tigermed, ProPhase, and Zhaoyan New Drug [11]. - Medical devices: United Imaging Healthcare and HaiTai New Light [11]. - Biopharmaceuticals: I-Mab Biopharma and Hualan Biological Engineering [11]. - It also suggests focusing on companies with innovative drug pipelines and those that are transitioning from biotech to biopharma [11]. Company Performance - The report provides a list of recommended stocks, including: - WuXi AppTec (66.45), rated "Buy" - Three Life Pharmaceuticals (29.34), rated "Buy" - Tigermed (49.59), rated "Buy" - Xiansheng Pharmaceutical (12.85), rated "Buy" - Betta Pharmaceuticals (48.60), rated "Buy" [5][31]. Regulatory and Market Trends - The report discusses recent regulatory developments, including a call from the vaccine industry association to avoid low-cost bidding practices to stabilize profit margins for leading vaccine companies [11][12]. - It also notes significant acquisitions and advancements in drug development, such as Johnson & Johnson's acquisition of Halda Therapeutics for $30.5 billion [11].

Core Points - Boda Pharmaceutical's stock price decreased by 2.08% on November 21, reaching 49.06 CNY per share, with a market capitalization of 20.641 billion CNY [1] - The company has experienced a year-to-date stock price decline of 8.69%, with a 9.68% drop over the last five trading days and a 23.44% decline over the past 60 days [1] - As of September 30, 2025, Boda Pharmaceutical reported a revenue of 2.717 billion CNY, a year-on-year increase of 15.90%, while the net profit attributable to shareholders decreased by 23.86% to 317 million CNY [2] Financial Performance - The company has distributed a total of 669 million CNY in dividends since its A-share listing, with 184 million CNY distributed over the last three years [3] - As of September 30, 2025, the number of shareholders decreased by 7.99% to 29,500, while the average number of circulating shares per person increased by 8.68% to 14,198 shares [2] Shareholder Structure - Among the top ten circulating shareholders, Xingshan Commercial Model Mixed Fund A is the fifth largest with 5.827 million shares, marking a new entry [3] - E Fund's Growth Enterprise Board ETF, ranked sixth, reduced its holdings by 912,300 shares to 5.456 million shares [3] - Xingshan Helun Mixed Fund A is the seventh largest shareholder with 5.402 million shares, also a new entry [3]

令人惊讶的是，这一估值背后是一个仅有47名员工的团队。截至2025年6月30日，公司研发相关人员 （药物发现与临床前开发+临床开发）共有31人，其余16人为一般与行政人员。在生物制药行业，这几 乎是一个"微型"团队。按估值计算，人均价值近4700万元。 然而，财务数据却呈现出另一番现实。 2023年7月，公司发生高管变更，财务负责人由潘家喆变更为王丽；2025年9月，公司财务负责人由王丽 变更为刘扬。王丽目前仍在公司实控人孝作祥控制的另一家企业——昊迈（杭州）企业管理咨询有限公 司中担任财务负责人，这家公司还是时迈药业的控股股东之一。但公司招股书中，并未披露王丽的离任 及履历情况。 在更早的2021年，公司还曾有另一位财务负责人。根据上市公司初灵信息（300250）2021年8月发布的 公告，严思恩是该公司的独立董事。在严思恩的简历中，初灵信息表示，严思恩现任公司独立董事、浙 江时迈药业有限公司CFO（首席财务官）、金华思来文化传媒有限公司经理、执行董事。 这也意味着，从2021年至2025年，时迈药业相继有严思恩、潘家喆、王丽和刘扬这四任财务负责人。 深圳报业集团旗下财中社在近日发布的报道《可能永远无法盈利 ...

Core Viewpoint - Benda Pharmaceutical's stock has experienced a decline in recent trading sessions, with a notable drop in both share price and market capitalization, indicating potential challenges in the company's performance and investor sentiment [1][2]. Company Performance - As of September 30, Benda Pharmaceutical reported a revenue of 2.717 billion yuan, reflecting a year-on-year growth of 15.90%. However, the net profit attributable to shareholders decreased by 23.86% to 317 million yuan [2]. - The company's stock price has fallen by 5.40% year-to-date, with a 5.71% decline over the past five trading days, a 12.75% drop over the last 20 days, and a significant 27.60% decrease over the past 60 days [1]. Shareholder Information - The number of shareholders decreased by 7.99% to 29,500, while the average number of circulating shares per person increased by 8.68% to 14,198 shares [2]. - Benda Pharmaceutical has distributed a total of 669 million yuan in dividends since its A-share listing, with 184 million yuan distributed over the past three years [3]. Institutional Holdings - As of September 30, 2025, notable institutional shareholders include Xingquan Commercial Model Mixed Fund (LOF) A, which is the fifth-largest shareholder with 5.827 million shares, and E-Fund's Growth Enterprise Board ETF, which has reduced its holdings by 912,300 shares [3].

杭州市生物医药产业近年来实现了跨越式发展，成为全国重要的生物医药创新高地。从2000年到 2024年，总产值从40亿元增长到超1000亿元，现有规上工业企业超300家。然而，随着产业的枝繁叶 茂，推动协同创新，正成为大家共同的期盼。 日前，全市生物医药产业科技创新和产业创新融合对接座谈会举行。记者冒着淅淅沥沥的秋雨赶到 会场，推开门，暖意扑面而来——回字形摆放的会议桌前坐得满满当当，大家翻阅着面前的会议资料， 了解高校、科研院所、医疗机构和企业的情况。 "组织这场活动，就是希望搭建一个平台，让'科研端'的智慧与'产业端'的需求能够直接对话。"主 持人开门见山。 听到高等院校、科研院所代表提到的先进技术，贝达药业股份有限公司副总裁兰宏尤其兴奋。"我 们非常感兴趣！"他说，"作为企业研发人员，我认为企业更擅长临床阶段，比如把有苗头的分子进一步 优化，推进临床开发，而这个苗头分子的出现是我们需要寻找的，非常希望与科技创新界建立合作。" 雨声渐密，市经信局工作人员的笔记本记了满满两页纸，"我们会尽快梳理交流成果，推动各方需 求与资源的精准匹配，让今天的'好想法'变成未来的'好项目'。" 散会时已是黄昏，但参会代表们都 ...